Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic disease (REACtiVe-2 Trial)

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all
of the following criteria:

• Metastatic pancreatic cancer as defined by the presence of radiologically
suspect metastatic lesions.
• Inclusion <= 4 weeks after stopping FOLFIRINOX chemotherapy.
• No more than 1 line of chemotherapy for metastatic disease is allowed. Prior
FOLFIRINOX for locally advanced disease if given within 1 year before screening
will be counted as first-line treatment. Any FOLFIRINOX given in the curative
intent setting if more than a year before screening will not be considered
first line therapy.
• An accessible metastasistic lesion for histological tissue collection.
• Patients must be at least 18 years old and must be able to give written
informed consent.
• WHO performance status 0-1.
• Patients must have normal organ function and adequate bone marrow reserve:
absolute neutrophil count > 1.0 x 109/l, platelet count > 100 x 109/l, and Hb >
6.0 mmol/l (as determined during screening). Transfusion in the 2 weeks
preceding screening is not allowed.
• Laboratory tests: ASAT/ALAT <5xULN (upper limit of normal), bilirubine
<1.5xULN, Creatinine value <1.5xULN, Lactate dehydrogenase value <= ULN and
albumin value >= LLN (lower limit of normal).
• Women of childbearing potential must have a negative serum pregnancy test at
screening and a negative urine pregnancy test just prior to the first study
drug administration on Day 1, and must be willing to use an effective
contraceptive method (intrauterine devices, hormonal contraceptives,
contraceptive pill, implants, transdermal patches, hormonal vaginal devices,
infusions with prolonged release) or true abstinence (when this is in line with
the preferred and usual lifestyle)* during the study and for at least 12 months
after the last study drug administration.
*True abstinence is acceptable when this is in line with the preferred and
usual lifestyle of the subject. Periodic abstinence (such as calendar,
ovulation, symptothermal, postovulation methods) and withdrawal are not
acceptable methods of contraception.
• Men must be willing to use an effective contraceptive method (e.g. condom,
vasectomy) during the study and for at least 12 months after the last study
drug administration.
• Ability to return to the hospital for adequate follow-up as required by this
protocol.
• Written informed consent according to ICH-GCP.

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded
from participation in this study:

• Medical or psychological impediment to probable compliance with the protocol.
• Abdominal ascites.
• Current or previous use of a CD40 antibody and/or anti-tumor vaccinations.
• Current use of steroids (or other immunosuppressive agents). Patients must
have had 6 weeks of discontinuation and must stop any such treatment during the
time of the study. Prophylactic usage of dexamethasone during chemotherapy is
excluded from this 6 weeks interval.
• Prior malignancy except adequately treated basal cell or squamous cell skin
cancer, superficial or in-situ cancer of the bladder or other cancer for which
the patient has undergone curative intent treatment and has been disease-free
for two years.
• Serious concomitant disease, or active infections.
• History of autoimmune disease, organ allografts or active acute or chronic
infection, including but not limited to HIV and viral hepatitis.
• Serious intercurrent chronic or acute illness such as pulmonary disease
(asthma or COPD), cardiac disease (NYHA class III or IV), hepatic disease or
other illness considered by the study coordinator to constitute an unwarranted
high risk for the investigational treatment.
• Known allergy to shell fish (may contain keyhole limpet hemocyanin (KLH)).
• Pregnant or lactating women.
• Inadequate vein access to perform leukapheresis.
• Concomitant participation in another clinical intervention trial (except
participation in a biobank study).
• An organic brain syndrome or other significant psychiatric abnormality which
would compromise the ability to give informed consent, and preclude
participation in the full protocol and follow-up.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study endpoint is dose-limiting toxicities of MesoPher/mitazalimab<br /><br>combination therapy. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are the radiographical response rate according to<br /><br>RECIST/iRECIST and systemic immune responses induced by the combination<br /><br>therapy.</p><br>

Related Trials